HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Luca A. Vricella Robert C. Robbins Richard I. Whyte Bruce A. Reitz Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vricella, L. A. Articles by Reitz, B. A. Search for Related Content PubMed PubMed Citation Articles by Vricella, L. A. Articles by Reitz, B. A. Related Collections Lung - transplantation

Ann Thorac Surg 2002;74:13-18
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the stanford experience

^a Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA

* Address reprint requests to Dr Vricella, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Falk CVRB, Stanford, CA 94305-5407, USA
e-mail: vricella{at}stanford.edu

Presented at the Forty-eighth Annual Meeting of the Southern Thoracic Surgical Association, San Antonio, TX, Nov 8–10, 2001.

Background. Bilateral lung (BLTx) and heart-lung transplantation have gained wide acceptance as treatment of end-stage lung disease from cystic fibrosis. We reviewed our 13-year experience with thoracic transplantation for cystic fibrosis with an operative approach that favors use of cardiopulmonary bypass for BLTx.

Methods. Sixty-four patients with cystic fibrosis underwent heart-lung transplantation (n = 22, 34.4%) or BLTx (n = 42, 65.6%) between 1988 and 2000. Mean age and weight at transplantation were 29 ± 8 years and 51 ± 11 kg, respectively. Mean follow-up for survivors was 4.4 ± 3.6 years. Immunosuppression regimen included cyclosporine, tapered corticosteroids, azathioprine, and induction therapy with OKT3 (murine monoclonal antibodies) or rabbit antithymocyte globulin. Cardiopulmonary bypass was used in all but 5 patients (7.8%). However, in 8 (19%) of the 42 patients having BLTx, only the grafting of the second lung was performed with cardiopulmonary bypass.

Results. The operative mortality rate was 1.6%. The actuarial survival rates at 1 year, 3 years, 5 years and 10 years were 93.2%, 77.7%, 61.8%, and 48.1%, respectively, with no significant difference between BLTx and heart-lung transplantation. The major hospital complications were pneumonia (n = 11, 17.2%) and bleeding (n = 8, 12.5%). Clinically significant reperfusion injury was observed in 6 patients, 3 of whom required reintubation. Freedom from acute lung rejection beyond 1 year was 47.7%. One patient underwent late retransplantation, and 4 required bronchial stenting. Obliterative bronchiolitis accounted for eight (50.0%) of 16 late deaths.

Conclusions. Though postoperative bleeding and pneumonia are still of concern, satisfactory early and intermediate-term results can be expected in patients undergoing BLTx or heart-lung transplantation for cystic fibrosis. Cardiopulmonary bypass can be used for BLTx with no adverse impact on intermediate and long-term outcomes.

This article has been cited by other articles:

				J. S. Ganesh, C. A. Rogers, R. S. Bonser, N. R. Banner, and on behalf of the steering group of the UK Cardioth Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study Eur. Respir. J., June 1, 2005; 25(6): 964 - 969. [Abstract] [Full Text] [PDF]